Lloyd Doggett
Trade Performance Intelligence
Score: 8/10Performance calculated from trade date to most recent market close. Real-time stock data from Financial Modeling Prep. This is not financial advice.
Stock Price at Trade vs. Today
Real market data showing how each stock moved since the congress member traded it.
Suspicious Timing Detected
5 flagsLloyd Doggett bought $1,001 - $15,000 in $IBM on 2026-03-10, 6 days before S4098, "A bill to establish standards and guidelines to make open Government data assets artificial intelligence-ready, and for other purposes," was introduced.
Lloyd Doggett bought $1,001 - $15,000 in $JNJ on 2026-03-10, 8 days before HR7980, the "Protecting Americans from Unsafe Drugs Act of 2026," which could increase compliance costs for pharmaceutical companies.
Lloyd Doggett bought $1,001 - $15,000 in $IBM on 2026-03-10, 9 days before S3952, the "Future of Artificial Intelligence Innovation Act of 2026," which could benefit AI development companies.
These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
| Type | Ticker | Asset | Amount | Trade Price | Current | Change | Date |
|---|---|---|---|---|---|---|---|
| BUY | $HD | Home Depot, Inc. | $1K-$15K | — | — | — | Mar 26, 2026 |
| BUY | $IBM | International Business Machines Corporation Common Stock | $1K-$15K | $250.20 | $237.18 | -5.2% | Mar 10, 2026 |
| BUY | $JNJ | Johnson & Johnson Common Stock | $1K-$15K | $243.71 | $241.31 | -1.0% | Mar 10, 2026 |
| BUY | $PPG | PPG Industries, Inc. Common Stock | $1K-$15K | — | — | — | Mar 12, 2026 |
Connected Legislative Activity
10 signalsThese bills and contracts share tickers or sectors with this filing's trades.
Protecting Americans from Unsafe Drugs Act of 2026
The 'Protecting Americans from Unsafe Drugs Act of 2026' expands drug recall authority to all drugs, increasing compliance costs and liability for pharmaceutical manufacturers. This directly elevates operational expenses and risks for major pharmaceutical companies. The bill creates a significant headwind for the pharmaceutical sector.
A bill to establish standards and guidelines to make open Government data assets artificial intelligence-ready, and for other purposes.
S.4098, the Artificial Intelligence-Ready Data Act, has been introduced in the Senate and referred to committee. This bill directs NIST to develop standards for making government data AI-ready, which could create new market opportunities for technology and consulting firms specializing in data management and AI solutions. No specific funding is authorized by this bill.
To require the Secretary of State, in consultation with the Secretary of Health and Human Services and other relevant departments and agencies, as appropriate, to formulate a strategy for the Federal Government to secure support from foreign countries, multilateral organizations, and other appropriate entities to facilitate the development and commercialization of qualified pandemic or epidemic products, and for other purposes.
HR7879, the "SUPER BUGS Act of 2026," introduced on March 9, 2026, directs the Secretary of State to formulate a strategy for international collaboration on pandemic product development. This bill is in its early stages, referred to the House Committee on Foreign Affairs, and does not authorize specific funding, thus having no immediate direct financial impact on companies. However, it signals potential future policy that could benefit pharmaceutical and biotechnology companies by expanding global market access for qualified pandemic or epidemic products.
To amend the National Quantum Initiative Act to upgrade and improve access to quantum research resources, and for other purposes.
HR8237, a bill to amend the National Quantum Initiative Act, has been introduced in the House and referred to the House Committee on Science, Space, and Technology. This early-stage bill aims to improve access to quantum research resources, which could structurally benefit companies engaged in quantum computing and related technologies.
To amend title XVIII of the Social Security Act to require PDP sponsors of a prescription drug plan under part D of the Medicare program that use a formulary to include certain generic drugs and biosimilar biological products on such formulary, and for other purposes.
HR8143 mandates Medicare Part D plans to include generic and biosimilar drugs on formularies, directly reducing brand-name drug sales and increasing generic/biosimilar market share. This legislation will decrease pharmaceutical company revenues from patented drugs and lower pharmacy benefit manager (PBM) margins on brand-name drugs.
Most Favored Patient Act of 2026
The Most Favored Patient Act of 2026 (HR7837) has been introduced in the House, proposing a most-favored-nation drug pricing model for Medicare-covered drugs by January 1, 2029. This bill, if enacted, would directly reduce revenue for major pharmaceutical companies by mandating the lowest global drug prices. The bill is currently in the early stages of the legislative process, having been referred to the Committees on Energy and Commerce and Ways and Means.
Future of Artificial Intelligence Innovation Act of 2026
The 'Future of Artificial Intelligence Innovation Act of 2026' establishes a comprehensive framework for AI development, directly benefiting companies in AI hardware, software, and services through increased government investment and procurement. This bill creates new revenue streams and accelerates market growth for leading tech firms. The bipartisan sponsorship ensures high legislative momentum and probable passage.
To require the Secretary of Health and Human Services to establish a demonstration program to test mandatory coverage of treatment for wound care for epidermolysis bullosa under the Medicaid program.
HR7877, the "Shane DiGiovanna Act," introduced on March 9, 2026, mandates a nationwide Medicaid demonstration program for epidermolysis bullosa wound care, creating a new, guaranteed revenue stream for pharmaceutical and medical supply companies. This bill directly increases demand for specific over-the-counter medications and wound care supplies by expanding covered services under Medicaid.
To amend the Public Health Service Act with respect to the Living Organ Donation Reimbursement Program.
The 'Expanding Support for Living Donors Act of 2026' directly increases financial incentives for living organ donation, expanding eligibility and raising reimbursement caps to $10,000 for fiscal year 2027. This will increase the supply of organs for transplant, driving demand for transplant-related medical services and technologies, directly benefiting healthcare companies in diagnostics, procedures, and post-operative care.
To amend title XVIII of the Social Security Act to ensure equitable payment for, and preserve Medicare beneficiary access to, cancer treatments under the Medicare hospital outpatient prospective payment system.
HR8032 stabilizes Medicare reimbursement for cancer treatments in outpatient settings, directly benefiting pharmaceutical and biotech companies focused on oncology. This legislation secures revenue streams for cancer drug manufacturers by creating a predictable financial environment for cancer care providers and drug suppliers. Companies with significant oncology portfolios see immediate upside.
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.